Literature DB >> 28238064

Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by diethylnitrosamine.

Yong-Fang Ding1,2, Zhen-Hui Wu3, Ying-Jie Wei1,2, Luan Shu1,2, Yun-Ru Peng4,5.   

Abstract

PURPOSE: Hepatocellular carcinoma (HCC) cases are closely associated with chronic inflammation and fibrosis which is known as hepatic inflammation-fibrosis-cancer (IFC) axis. The aim of this study is to elucidate the development characteristics of the rat HCC model based on IFC axis.
METHODS: The diethylnitrosamine (DEN)-induced rat HCC, which presents a stepwise histopathological progression that is similar to human HCC, was used to analyze the features of the different stages (inflammation, fibrosis, cancer). Rats were injected DEN at a dose of 30 mg/kg body weight twice a week for 11 weeks and the animals were observed until week 20. Time series sera and organ samples from the DEN animal model were collected to evaluate the dynamic changes.
RESULTS: It was found that serum biochemical indicators (AST, ALT, ALP, TP, T-BIL, IL-6, TNF-α) from DEN-treated group were higher than that from control group. Fibrosis-related index in serum and live tissue were increased, respectively, from week 4 after DEN treatment. The expression of TGF-β1 and α-SMA in DEN-treated group was higher than that in control group. JAK2/STAT3 signaling was significantly up-regulated in DEN-treated group compared to that in control group. The histological examination confirmed that the hepatocarcinogenesis model was successfully established, and 100% of the animals in the DEN-exposed group developed liver tumors at 20 weeks. According to the pathological changes, the model characterized resulted in three stages: the inflammation stage (week 2-6), the fibrosis stage (week 8-12), and the HCC stage (week 14-20).
CONCLUSIONS: The results suggested that the HCC development was associated with IFC axis. The serial progression of hepatocarcinogenesis was according to the sequence of hepatic inflammation, fibrosis and then hepatic tumor.

Entities:  

Keywords:  Hepatocellular carcinoma; Inflammation-fibrosis-cancer (IFC) axis; Liver fibrosis; Liver inflammation

Mesh:

Substances:

Year:  2017        PMID: 28238064     DOI: 10.1007/s00432-017-2364-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  28 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response.

Authors:  Yoshihiko Tachi; Takanori Hirai; Akihiro Miyata; Kei Ohara; Tadashi Iida; Youji Ishizu; Takashi Honda; Teiji Kuzuya; Kazuhiko Hayashi; Masatoshi Ishigami; Hidemi Goto
Journal:  Hepatol Res       Date:  2014-04-24       Impact factor: 4.288

Review 3.  Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?

Authors:  Vincent Wai-Sun Wong; Harry L A Janssen
Journal:  J Hepatol       Date:  2015-05-27       Impact factor: 25.083

4.  The DEN and CCl4 -Induced Mouse Model of Fibrosis and Inflammation-Associated Hepatocellular Carcinoma.

Authors:  Takeki Uehara; Igor P Pogribny; Ivan Rusyn
Journal:  Curr Protoc Pharmacol       Date:  2014-09-02

5.  Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease.

Authors:  Paul Calès; Jérôme Boursier; Julien Chaigneau; Fabrice Lainé; Jeremy Sandrini; Sophie Michalak; Isabelle Hubert; Nina Dib; Frédéric Oberti; Sandrine Bertrais; Gilles Hunault; Christine Cavaro-Ménard; Yves Gallois; Yves Deugnier; Marie C Rousselet
Journal:  Liver Int       Date:  2010-10       Impact factor: 5.828

Review 6.  Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.

Authors:  Virginia Hernandez-Gea; Sara Toffanin; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2013-01-09       Impact factor: 22.682

Review 7.  Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis.

Authors:  Ahmed M Elsharkawy; Derek A Mann
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

8.  High-saturate-fat diet delays initiation of diethylnitrosamine-induced hepatocellular carcinoma.

Authors:  Xiao-Yan Duan; Qin Pan; Shi-Yan Yan; Wen-Jin Ding; Jian-Gao Fan; Liang Qiao
Journal:  BMC Gastroenterol       Date:  2014-11-20       Impact factor: 3.067

9.  Deletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice.

Authors:  Lingxiang Kong; Yongjie Zhou; Hong Bu; Tao Lv; Yujun Shi; Jiayin Yang
Journal:  J Exp Clin Cancer Res       Date:  2016-09-02

10.  Pharmacokinetics and tissue distribution study of caudatin in normal and diethylnitrosamine-induced hepatocellular carcinoma model rats.

Authors:  Yunru Peng; Yongfang Ding
Journal:  Molecules       Date:  2015-03-05       Impact factor: 4.411

View more
  19 in total

1.  Effects of sub-chronic exposure to atmospheric PM2.5 on fibrosis, inflammation, endoplasmic reticulum stress and apoptosis in the livers of rats.

Authors:  Ruijin Li; Mei Zhang; Ying Wang; Ken Kin Lam Yung; Ruijun Su; Zhuoyu Li; Liping Zhao; Chuan Dong; Zongwei Cai
Journal:  Toxicol Res (Camb)       Date:  2018-01-10       Impact factor: 3.524

2.  Profiling Carbohydrate Metabolism in Liver and Hepatocellular Carcinoma with [13C]-Glycerate Probes.

Authors:  Jun Chen; Evan LaGue; Junjie Li; Chendong Yang; Edward P Hackett; Manuel Mendoza; Jeffry R Alger; Ralph J DeBerardinis; Ian R Corbin; Kelvin L Billingsley; Jae Mo Park
Journal:  Anal Sens       Date:  2021-09-14

Review 3.  Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

Authors:  David H Ipsen; Jens Lykkesfeldt; Pernille Tveden-Nyborg
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

4.  Dietary modulations of folic acid affect the development of diethylnitrosamine induced hepatocellular carcinoma in a rat model.

Authors:  Renuka Sharma; Taqveema Ali; Ishwar Negi; Ashim Das; Ajay Duseja; Jyotdeep Kaur
Journal:  J Mol Histol       Date:  2021-01-13       Impact factor: 2.611

5.  Copper Mediates Anti-Inflammatory and Antifibrotic Activity of Gleevec in Hepatocellular Carcinoma-Induced Male Rats.

Authors:  Iftekhar Hassan; Hossam Ebaid; Ibrahim M Alhazza; Jameel Al-Tamimi; Shazia Aman; Ahmad M Abdel-Mageed
Journal:  Can J Gastroenterol Hepatol       Date:  2019-03-03

6.  Baishouwu Extract Suppresses the Development of Hepatocellular Carcinoma via TLR4/MyD88/NF-κB Pathway.

Authors:  Yong-Fang Ding; Zi-Xuan Peng; Lan Ding; Yun-Ru Peng
Journal:  Front Pharmacol       Date:  2019-04-24       Impact factor: 5.810

7.  The Carcinogenic Agent Diethylnitrosamine Induces Early Oxidative Stress, Inflammation and Proliferation in Rat Liver, Stomach and Colon: Protective Effect of Ginger Extract.

Authors:  Dina F Mansour; Heba M I Abdallah; Bassant M M Ibrahim; Rehab R Hegazy; Reham S E Esmail; Lubna O Abdel-Salam
Journal:  Asian Pac J Cancer Prev       Date:  2019-08-01

8.  Restrained management of copper level enhances the antineoplastic activity of imatinib in vitro and in vivo.

Authors:  Iftekhar Hassan; Azmat Ali Khan; Shazia Aman; Wajhul Qamar; Hossam Ebaid; Jameel Al-Tamimi; Ibrahim M Alhazza; Ahmed M Rady
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

9.  Total C-21 steroidal glycosides, isolated from the root tuber of Cynanchum auriculatum Royle ex Wight, attenuate hydrogen peroxide-induced oxidative injury and inflammation in L02 cells.

Authors:  Zhenhui Wu; Yingyu Wang; Xian Meng; Xinjie Wang; Zhenlin Li; Shihui Qian; Yingjie Wei; Luan Shu; Yongfang Ding; Peijuan Wang; Yunru Peng
Journal:  Int J Mol Med       Date:  2018-09-25       Impact factor: 4.101

10.  Water-Soluble Pristine C60 Fullerenes Inhibit Liver Fibrotic Alteration and Prevent Liver Cirrhosis in Rats.

Authors:  Halyna Kuznietsova; Natalia Dziubenko; Vasyl Hurmach; Iryna Chereschuk; Olexandr Motuziuk; Olexandr Ogloblya; Yuriy Prylutskyy
Journal:  Oxid Med Cell Longev       Date:  2020-02-13       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.